诊断学理论与实践

诊断学理论与实践 >

2019 , Vol. 18 >Issue 06: 685 - 671

DOI: https://doi.org/10.16150/j.1671-2870.2019.06.017

综述

二代测序技术在骨髓增生异常综合征临床诊断和治疗决策中的应用进展

展开
  • 1.上海金域医学检验所有限公司,上海 201321
    2.广州金域临床基因组中心,广东 广州 510320
    3.上海交通大学附属第六人民医院血液科,上海 200233

收稿日期: 2018-10-19

  网络出版日期: 2019-12-25

收起

本文引用格式

杜云志, 冯菁华, 常春康 . 二代测序技术在骨髓增生异常综合征临床诊断和治疗决策中的应用进展[J]. 诊断学理论与实践, 2019 , 18(06) : 685 -671 . DOI: 10.16150/j.1671-2870.2019.06.017

参考文献

[1] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[2] Ma X. Epidemiology of myelodysplastic syndromes[J]. Am J Med, 2012, 125(7 Suppl):S2-S5.
[3] Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries[J]. Leukemia, 2005, 19(5):767-775.
[4] Irons RD, Wang X, Gross SA, et al. Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications[J]. Leuk Res, 2006, 30(7):769-775.
[5] Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes[J]. Blood, 2015, 126(1):9-16.
[6] NCCN guideline version 2. 2019 Myelodysplastic syndromes[DB/OL]. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
[7] Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes[J]. N Engl J Med, 2011, 364(26):2496-2506.
[8] Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms[J]. Blood, 2011, 118(24):6239-6246.
[9] Kohlmann A, Bacher U, Schnittger S, et al. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing[J]. Leuk Lymphoma, 2014, 55(8):1725-1734.
[10] Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes[J]. J Clin Oncol, 2012, 30(27):3376-3382.
[11] Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes[J]. Blood, 2012, 120(12):2454-2465.
[12] Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders[J]. Blood, 2013, 122(18):3169-3177.
[13] Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes[J]. Blood, 2013, 122(22):3616-3627.
[14] 宋陆茜, 常春康. 二代测序技术在骨髓增生异常综合征诊治中的临床应用[J]. 诊断学理论与实践, 2016, 15(6):556-559.
[15] Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes[J]. Blood, 2014, 124(18):2793-2803.
[16] Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients[J]. Blood, 2014, 124(17):2705-2712.
[17] Klimek VM. It dices, it splices![J]. Blood, 2011, 118(24):6237-6238.
[18] Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation[J]. N Engl J Med, 2017, 376(6):536-547.
[19] Jädersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression[J]. J Clin Oncol, 2011, 29(15):1971-1979.
[20] Haase D, Stevenson KE, Neuberg D, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups[J]. Leukemia, 2019, 33(7):1747-1758.
[21] Mallo M, Del Rey M, Ibáñez M, et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations[J]. Br J Haematol, 2013, 162(1):74-86.
[22] Xu J, Reumers J, Couceiro JR, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors[J]. Nat Chem Biol, 2011, 7(5):285-295.
[23] McClure RF, Ewalt MD, Crow J, et al. Clinical significance of DNA variants in chronic myeloid neoplasms: A report of the association for molecular pathology[J]. J Mol Diagn, 2018, 20(6):717-737.
[24] Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of next-generation sequencing-based oncology panels: A joint consensus recommendation of the Associa-tion for Molecular Pathology and College of American Pathologists[J]. J Mol Diagn, 2017, 19(3):341-365.
[25] Roy S, Coldren C, Karunamurthy A, et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: A joint recommendation of the Association for Molecular Pathology and the College of American Pathologists[J]. J Mol Diagn, 2018, 20(1):4-27.
[26] Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists[J]. J Mol Diagn, 2017, 19(1):4-23.
[27] Aziz N, Zhao Q, Bry L, et al. College of American Patho-logists' laboratory standards for next-generation sequen-cing clinical tests[J]. Arch Pathol Lab Med, 2015, 139(4):481-493.
[28] 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会, 中华医学会病理学分会.二代测序技术在血液肿瘤中的应用中国专家共识(2018年版)[J]. 中华血液学杂志, 2018, 39(11):881-886.
Options
文章导航

/

〈 〉